Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12544634 | 1.00 | MET (0.42) | METDYRK1AGSK3BKDRWNT1 | |
| SCHEMBL2175368 | 0.90 | MET (0.45) | METDYRK1AKDRWNT1 | |
| SCHEMBL29773380 | 0.88 | MET (0.43) | METDYRK1AGSK3BKDRWNT1 | |
| SCHEMBL12693353 | 0.88 | MET (0.43) | METDYRK1AGSK3BKDRWNT1 | |
| SCHEMBL2361649 | 0.84 | MET (0.48) | METDYRK1AKDRWNT1 | |
| SCHEMBL12544010 | 0.84 | ALOX5 (0.40) | KDR | |
| SCHEMBL30779384 | 0.84 | ALOX5 (0.40) | KDR | |
| SCHEMBL12544633 | 0.83 | DYRK1A (0.41) | METDYRK1AGSK3BKDRWNT1 | |
| SCHEMBL29773408 | 0.82 | MET (0.48) | METDYRK1A | |
| SCHEMBL2174986 | 0.82 | MET (0.48) | METDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | TK2, TYMP, DPYD | MET 3220/4885DYRK1A 1786/4885GSK3B 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.